Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 35Prostatic Neoplasms 26Carcinoma, Non-Small-Cell Lung 24Lung Neoplasms 15Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Carcinoma, Ovarian Epithelial 7Adenocarcinoma of Lung 7Inflammatory Breast Neoplasms 6Fallopian Tube Neoplasms 6Breast Neoplasms, Male 6Stomach Neoplasms 4Head and Neck Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Tongue Neoplasms 3Pain 3Neoplasm Metastasis 3Adenocarcinoma, Bronchiolo-Alveolar 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Pleural Effusion, Malignant 2Oropharyngeal Neoplasms 2Neoplasms 2Lymphoid Interstitial Pneumonia 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma 2Brenner Tumor 2

Interventions

veliparib 2Carboplatin 2prexasertib 1Taxes 1Paclitaxel 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hereditary Breast and Ovarian Cancer Syndrome × Docetaxel × Clear all
NCT00321633 2013-08-26

Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
148 enrolled
BreastGynecologic

Breast Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡